DK0719154T3 - Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel - Google Patents

Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel

Info

Publication number
DK0719154T3
DK0719154T3 DK94926591T DK94926591T DK0719154T3 DK 0719154 T3 DK0719154 T3 DK 0719154T3 DK 94926591 T DK94926591 T DK 94926591T DK 94926591 T DK94926591 T DK 94926591T DK 0719154 T3 DK0719154 T3 DK 0719154T3
Authority
DK
Denmark
Prior art keywords
factor viii
therapeutic agent
activated
deficiency
treating
Prior art date
Application number
DK94926591T
Other languages
English (en)
Inventor
Joseph Edward Curtis
Sam Leland Helgerson
Roger L Lundblad
Shu-Len Liu
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Application granted granted Critical
Publication of DK0719154T3 publication Critical patent/DK0719154T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK94926591T 1993-09-13 1994-08-26 Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel DK0719154T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/120,894 US5576291A (en) 1993-09-13 1993-09-13 Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
PCT/US1994/009613 WO1995007713A1 (en) 1993-09-13 1994-08-26 Activated factor viii as a therapeutic agent and method of treating factor viii deficiency

Publications (1)

Publication Number Publication Date
DK0719154T3 true DK0719154T3 (da) 2001-11-26

Family

ID=22393146

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94926591T DK0719154T3 (da) 1993-09-13 1994-08-26 Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel

Country Status (10)

Country Link
US (1) US5576291A (da)
EP (1) EP0719154B1 (da)
JP (1) JPH09502714A (da)
AT (1) ATE207759T1 (da)
AU (1) AU686661B2 (da)
CA (1) CA2168332A1 (da)
DE (1) DE69428905T2 (da)
DK (1) DK0719154T3 (da)
ES (1) ES2166783T3 (da)
WO (1) WO1995007713A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003332A1 (en) * 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
EP1820516B1 (en) 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
EP1194161B1 (en) * 1999-07-13 2005-11-23 Biovitrum Ab Stable factor viii compositions
JP4643783B2 (ja) * 1999-12-24 2011-03-02 一般財団法人化学及血清療法研究所 フォンヴィルブランド因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
CA2518327A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ATE463572T1 (de) * 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
EP2311437A1 (en) * 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
DE602006018622D1 (de) * 2005-06-30 2011-01-13 Ge Healthcare Bio Sciences Nachweisverfahren für die genexpression
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP2150264A4 (en) 2007-04-26 2014-09-24 Bayer Healthcare Llc STABILIZATION OF LIQUID SOLUTIONS OF A RECOMBINANT PROTEIN FOR FROZEN STORAGE
CA2703948A1 (en) * 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
US20180292420A1 (en) 2015-05-06 2018-10-11 Prescient Medicine Llc Development of novel automated screening method for detection of fviii inhibitors
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2460305A2 (fr) * 1979-06-29 1981-01-23 Merieux Inst Procede de preparation d'un concentre de facteur viii
US4386068A (en) * 1980-02-26 1983-05-31 Cutter Laboratories, Inc. Antihemophilic factor concentrate and method for preparation
AT369263B (de) * 1980-08-27 1982-12-27 Immuno Ag Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates
US4857635A (en) * 1983-03-31 1989-08-15 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies tof them
IE80858B1 (en) * 1983-03-31 1999-04-21 Scripps Research Inst New factor viii coagulant polypeptides
US4649132A (en) * 1983-03-31 1987-03-10 Scripps Clinic And Research Foundation Treatment of Factor VIII inhibitors
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
US5101016A (en) * 1983-03-31 1992-03-31 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies to them
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
DK525384D0 (da) * 1984-11-05 1984-11-05 Nordisk Insulinlab Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
MX9203440A (es) * 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
US4769336A (en) * 1985-05-24 1988-09-06 Scripps Clinic And Research Foundation Treatment of factor VIII inhibitors
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
CA1331157C (en) * 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
IE69026B1 (en) * 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US4795806A (en) * 1987-07-16 1989-01-03 Miles Laboratories, Inc. Phospholipid affinity purification of Factor VIII:C
US4981951A (en) * 1988-04-14 1991-01-01 Miles Inc. Lectin affinity chromatography of factor VIII
US5149687A (en) * 1991-04-01 1992-09-22 United Technologies Corporation Method for making oriented bismuth and thallium superconductors comprising cold pressing at 700 MPa

Also Published As

Publication number Publication date
DE69428905D1 (de) 2001-12-06
WO1995007713A1 (en) 1995-03-23
DE69428905T2 (de) 2002-05-29
EP0719154B1 (en) 2001-10-31
JPH09502714A (ja) 1997-03-18
AU7638094A (en) 1995-04-03
AU686661B2 (en) 1998-02-12
US5576291A (en) 1996-11-19
EP0719154A1 (en) 1996-07-03
ES2166783T3 (es) 2002-05-01
ATE207759T1 (de) 2001-11-15
CA2168332A1 (en) 1995-03-23

Similar Documents

Publication Publication Date Title
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
NO961888D0 (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DE60139078D1 (de) Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser-sehkraftkorrektur-chirurgie
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
ES2133807T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
SE9404196D0 (sv) New antithrombotic formulation
WO2001041753A3 (en) Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds
DK0674511T3 (da) Antipyretiske og analgetiske fremgangsmåder og midler indeholdende optisk rent R-ketorolac
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DK71387D0 (da) Terapeutisk middel til behandling af psoriasis
ATE78171T1 (de) Gangliosidgemisch zur verwendung als therapeutisches hilfsmittel zur schmerzunterdrueckung bei peripheren neuropathien.
SE9603725D0 (sv) New teatment
DE69310528D1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
DE69333413D1 (de) 5-ht2-antagonisten in der behandlung venöser zustände
DK0579488T3 (da) Præparat til behandling af mastitis og matritis
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe